Cardiff Oncology
CRDF
105 hedge funds and large institutions have $24.2M invested in Cardiff Oncology in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 31 closing their positions.
2,888% more call options, than puts
Call options by funds: $956K | Put options by funds: $32K
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
8.6% less ownership
Funds ownership: 35.98% → 27.38% (-8.6%)
10% less funds holding
Funds holding: 117 → 105 (-12)
32% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 31
39% less capital invested
Capital invested by funds: $39.7M → $24.2M (-$15.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$901K |
| 2 |
LCM
Laurion Capital Management
New York
|
+$717K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$445K |
| 4 |
HF
HRT Financial
New York
|
+$433K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$378K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.78M |
| 2 |
ACA
Acorn Capital Advisors
New York
|
-$2.85M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.36M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.24M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$580K |
CRDF Hedge Fund Activity: Q2 2026 in Review
105 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2026, worth a combined $24.2M — down 39% from $39.7M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of CRDF and 21 opened new positions — a net loss of 10 holders — while 26 trimmed existing stakes and 34 added.
The largest buyer was Jane Street, adding an estimated $901K. The largest seller was BlackRock, cutting an estimated $4.78M.
- 105 institutional investors held Cardiff Oncology (CRDF) as of Q2 2026, down from 117 in Q1 2026.
- Funds reported $24.2M of Cardiff Oncology stock for Q2 2026, down 39% quarter-over-quarter.
- 21 funds opened new Cardiff Oncology positions in Q2 2026 and 31 closed out, a net change of -10 holders.
- The largest Cardiff Oncology buyer in Q2 2026 was Jane Street, an estimated $901K added.
- The largest Cardiff Oncology seller in Q2 2026 was BlackRock, an estimated $4.78M sold.
Based on aggregated 13F filings for Q2 2026.